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Significance and Impact of the Study: This study shows new insights regarding recurrent candidiasis.
The authors demonstrated that Amphotericin B did not totally prevent the development of biofilms
during Candida glabrata’s infection treatment and that the change in the biofilm matrices may have a
high responsibility for the fail in the treatment of systemic candidiasis.
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Abstract
Candida species are responsible for recurrent human infections, mostly in
immunocompromised patients, due to their high vulnerability. Candida
glabrata has a major role in systemic candidiasis and Amphotericin B (AmB), a
polyene only used in hospitals, is frequently used to treat this disease. Lately,
however, clinical evidences of Candida recurrent infections during these
treatments are being described, probably due to biofilm (re)formation during
this therapy. Thus, this work aims at inferring if C. glabrata biofilms are still
being formed during AmB treatment. For that, C. glabrata biofilms were
formed in the presence of AmB and analysed by dry weight. Matrix
composition was analysed quantifying carbohydrates and, specifically, b-1,3
glucans. Results demonstrated that, although in a lesser extent, C. glabrata is
able to develop biofilms in the presence of AmB, with a thick extracellular
matrix, with an increase on carbohydrates, especially b-1,3 glucans. Therefore,
it is confirmed that complex biofilms of C. glabrata can be formed during an
AmB treatment.
Introduction
Infections caused by Candida species are a problem of
increasing clinical significance, which can result in septi-
caemia or systemic infections, with high morbility and
mortality (Lass-Fl€orl 2009). Candida can be found in the
gastrointestinal, genital and urinary tract of healthy indi-
viduals as innocuous commensals. However, in immuno-
compromised and/or hospitalized hosts they are able to
cause superficial infections, which may lead to invasive
and very critical complications. In addition, Candida pos-
sess high capability to adapt to different niches and to
invade several epithelia, resulting in septicaemia (Ellis
2002; Lass-Fl€orl 2009).Yet, Amphotericin B, a fungicidal
polyene, has shown efficacy activity against many Candida
species (Ellis 2002; Krogh-Madsen et al. 2006; Vandeputte
et al. 2008; Baginski and Czub 2009; Laniado-Laborin
and Cabrales-Vargas 2009).
Among the several Candida species, Candida glabrata is
the one of the most prevalent pathogenic fungal species
in humans, after Candida albicans (West et al. 2013;
Angoulvant et al. 2016). Besides being very resistant to
antifungal agents (Ellis 2002; Krogh-Madsen et al. 2006;
Lass-Fl€orl 2009), and although lacking capability to pro-
duce hyphae, C. glabrata possess a number of virulence
factors, making it very aggressive. Among these are
included the adhesion to host cells or to medical devices
(e.g. catheters, algaliation devices) composed of silicone,
latex or polyurethane for example, the secretion of hydro-
lytic enzymes such as phospholipases and haemolysins,
and the biofilm formation capacity (Sanchez-Vargas et al.
2013; Rodrigues et al. 2014). These biofilms can be
formed on the host mucosa and/or on surfaces of medical
indwelling devices and are composed by yeast cells
embedded in a complex polymeric structure, which makes
them much more resistant to treatments than original
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planktonic cells (Sardi et al. 2013; Rodrigues et al. 2014;
d’Enfert and Janbon 2016). Moreover, it was already
shown that even after standard treatment of infections
caused by biofilms associated with medical devices, some
patients still undergo recurrent candidiasis (Mishra et al.
2007).
Therefore, the main goal of this work was to under-
stand why C. glabrata infections are still recurrent even
during the patient’s treatment with AmB, by evaluation
of its capacity to form biofilms.
Results and discussion
The ability of Candida glabrata to form biofilms in the
presence of AmB was determined by dry weight (Table 1).
Candida glabrata 534784 showed higher capacity to pro-
duce biofilms, compared with the other two strains
(Table 1), which can also be noticed in the SEM images
(Fig. 1I, II and III). Importantly, it can be remarked that
biofilms are, in fact, still being developed by the three
strains in the presence of AmB to a lesser extent and they
even present a considerable amount of biomass, except for
C. glabrata 562123, in the presence of the highest concen-
tration of AmB (Table 1). It should also be highlighted
that this corresponds to usual therapeutic doses.
SEM images (Fig. 1) confirmed that, although
C. glabrata biofilm formation is reduced in the presence
of AmB, an organized structure can still be observed
(Fig. 1II and III). This allowed the consideration that
AmB could cause structural modifications on C. glabrata’s
biofilm, with the presence of a compact matrix. In fact,
one of the major contributions to C. glabrata virulence is
its versatility in being adapted to a variety of different
habitats and the formation of biofilms (Donlan and
Costerton 2002; Mishra et al. 2007; Sardi et al. 2013;
Angoulvant et al. 2016). There is a general consensus that
the biofilm matrix acts as a barrier to the diffusion of
antimicrobial agents, thereby limiting the access of the
antimicrobial to organisms at the lower layers of the bio-
film (Donlan and Costerton 2002; Mishra et al. 2007;
Sardi et al. 2013; Angoulvant et al. 2016). However, little
is known about the effect of the antifungal agent on the
matrix production and composition.
Thus, posteriorly, the evaluation of the matrix compo-
sition (Fig. 2) confirmed the presence of rich and mature
biofilm matrices in the presence of AmB. It was possible
to verify an increase in the amount of carbohydrates on
the matrix on the biofilms formed in the presence of
AmB (Fig. 2), especially of b-1,3 glucans (Table 2). b-1,3
glucans are polymers found in the cell wall of Candida
and in the biofilm matrix and are related to the antifun-
gal resistance, making it difficult for the drugs to diffuse
through the biofilm matrices (Lewis et al. 2012; Taff et al.
2012; Zarnowski et al. 2014). In fact, the increase of these
compounds in biofilm matrix is very notorious even
when there is a significant reduction in the total biofilms
(Table 1 and Fig. 1). Meaning that, even with a reduction
on the number of biofilm cells, the increase in biofilm
matrix is clear and maybe associated with the stress
caused by the antifungal agent.
It can be conjectured that AmB might be triggering the
production and secretion of carbohydrates, which may be
related with an attempt to make a physical protection for
the cells, against the antifungal aggression, as it has
already been demonstrated for C. albicans (Taff et al.
2012). In fact, glucan enzymes responsible for the produc-
tion of these carbohydrates seem to play a biofilm-specific
role in facilitating the delivery and organization of mature
biofilm matrices, being decisive for delivery of b-1,3 glu-
cans to the biofilm matrices and for accumulation of
mature matrices biomass (Taff et al. 2012).
Concluding, it was confirmed that C. glabrata can
develop biofilms in the presence of therapeutic concentra-
tions of AmB, due to the high carbohydrate and b-1,3
glucan concentrations quantified on the biofilm matrices,
highlighting the capacity of Candida cells to rapidly over-
come outside aggressions and realizing why patients
undergoing AmB treatment still manifest resilient Can-
dida infections. Besides, this high carbohydrate content,
specially b-1,3 glucans can also justify the biofilm cells’
high resistance to antifungal treatments that been typically
described for C. glabrata.
Material and methods
Organisms
Two clinical isolates of Candida glabrata (C. glabrata
534784 from vaginal site and C. glabrata 562123 from
urine) and one reference strain (C. glabrata ATCC 2001)
were used in this work. The identity of all isolates was
Table 1 Effect of amphotericin B on Candida glabrata’s biofilm




Dry weight of biofilm
mg  SD (P value)
ATCC2001 0 20  05
1 9 103 12  02***
2 9 103 10  05***
562123 0 20  04
1 9 103 10  00***
2 9 103 08  02***
534784 0 30  02
1 9 103 13  05***
2 9 103 16  06***
***P < 00001.
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confirmed using CHROMagar Candida (CHROMagar,
Paris, France) and by PCR-based sequencing using speci-
fic primers (ITS1 and ITS4) against the 58 s subunit gene
reference. Genomic DNA was extracted following previ-
ously described procedures (Williams et al. 1985). The






Figure 1 SEM images of Candida glabrata’s biofilms. Magnification: 10009. I – Biofilm grown without AmB; II – Biofilm grown with


























































Control    1×10–3 –3 2×10
[AmB] g l
C. glabrata ATCC2001 C. glabrata 562123 C. glabrata 534784
Control    1×10 2×10
[AmB] g l
Control    1×10 2×10
[AmB] g l–1
–3 –3 –3 –3 
–1–1
Figure 2 Carbohydrate content on Candida glabrata’s biofilms matrices with and without Amphotericin B (**P < 0001, ***P < 00001).
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Dye terminator cycle sequencing kit (Perkin Elmer,
Applied Biosystems, Warrington, UK).
Growth conditions
For each experiment, strains were subcultured on Sabour-
aud dextrose agar (SDA) (Merck, Darmstadt, Germany)
for 24 h at 37°C. Cells were then inoculated in Sabouraud
dextrose broth (SDB) (Merck) and incubated for 18 h at
37°C under agitation at 120 rotations per minute
(rpm min1). After incubation, the cells were harvested
by centrifugation at 3000 g for 10 min at 4°C and washed
twice with Phosphate-Buffered Saline (PBS, pH = 75).
Pellets were then suspended in SDB and the cellular den-
sity was adjusted to 1 9 105 cells ml1 using a Neubauer
counting chamber (Rodrigues et al. 2015).
Amphotericin B
AmB (Sigma-Aldrich, St Louis, MO), was prepared at
1 9 103 g l1 and 2 9 103 g l1, from a stock of
1 g l1 diluted in dimethylsulfoxyde.
Biofilm formation and analysis
Standardized cell suspensions were placed into selected
wells of 24-well polystyrene microtitre plates (Orange Sci-
entific, Braine-l‘Alleud, Belgium) plus 250 ll of each
duplicated concentration of antifungal agent to test
(1 9 103 g l1 and 2 9 103 g l1, final concentration).
As negative control, SDB without cells and antifungal
agent were used. As positive control, cells suspensions
were tested without an antifungal agent. After 24 h,
250 ll of SDB medium was removed and an equal vol-
ume of fresh SDB, plus the respective antifungal concen-
tration agent was added.
Dry weight was analysed to evaluate AmB effect on
biofilm production (Rodrigues et al. 2015).
In order to examine the structure of biofilms, after
formation in the presence or absence of AmB, they were
observed by scanning electron microscopy. For that, bio-
films formed as described above were dehydrated with
ethanol (using 70% ethanol for 10 min, 95% ethanol for
10 min and 100% ethanol for 20 min) and air-dried for
20 min. Samples were kept in a desiccator until the base
of the wells was removed for analysis. Prior to observa-
tion, the base of the wells were mounted onto alu-
minium stubs, sputter coated with gold and observed
with an S-360 scanning electron microscope (Leo, Cam-
bridge, MA).
Total carbohydrate content of the biofilm matrix was
estimated according to the procedure of DuBois et al.
(1956), using glucose as a standard. The values were nor-
malized per g of dry weight biofilm and the values were
presented as mg of carbohydrate/g of dry weight of biofilm.
b-1,3 glucans concentrations b-1,3 glucans concentra-
tions were determined using Glucatell kit (Cape Cod,
East Falmouth, MA). The values were normalized by mg
of b-1,3 glucans per g dry weight of biofilm.
All the experiments were performed in triplicate and in
three independent assays.
Statistical analysis
Results were compared using a one-way ANOVA, Dunnett’s
test, using GraphPad Prism 5 software (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). All tests were performed
with a confidence level of 95%.
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